Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Alumis Inc. ( (ALMS) ) just unveiled an update.
On February 6, 2025, Alumis Inc. announced a merger agreement with ACELYRIN, Inc., creating a combined company dedicated to developing transformative therapies for immune-mediated diseases. The all-stock transaction, subject to stockholder approval, will see Alumis and ACELYRIN stockholders owning approximately 55% and 45% of the combined entity, respectively. The merger is expected to expand Alumis’ late-stage pipeline, including ACELYRIN’s lonigutamab, and provide financial stability with a pro forma cash position of $737 million. The combined company will operate under the Alumis name, led by the current Alumis executive team, and aims to leverage its R&D success and proprietary data platform to advance its differentiated portfolio. The transaction is anticipated to close in the second quarter of 2025, with stockholders representing substantial shares of both companies already in support.
More about Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies using a precision approach to improve the lives of patients with immune-mediated diseases. The company leverages its proprietary precision data analytics platform to build a pipeline of molecules that can potentially address a wide range of immune-mediated diseases as monotherapy or combination therapies. Alumis’ most advanced product candidate is ESK-001, an oral, highly selective, small molecule, allosteric inhibitor.
YTD Price Performance: -13.26%
Average Trading Volume: 145,474
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $387.9M
See more insights into ALMS stock on TipRanks’ Stock Analysis page.
